T1	Participants 492 628	In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
T2	Participants 391 490	Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2
